Skip to content
The Policy VaultThe Policy Vault

Jakafi (ruxolitinib) — Medica

Myeloid or Lymphoid Neoplasms with Eosinophilia and JAK2 Rearrangement

Initial criteria

  • age ≥ 18 years
  • patient has eosinophilia
  • tumor has a Janus Associated Kinase 2 (JAK2) rearrangement

Approval duration

1 year